ImmunityBio Beheer
Beheer criteriumcontroles 2/4
De CEO ImmunityBio is Rich Adcock, benoemd in Oct2020, heeft een ambtstermijn van 5.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.72M, bestaande uit 6.5% salaris en 93.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.053% van de aandelen van het bedrijf, ter waarde $ 4.33M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 5.8 jaar.
Belangrijke informatie
Rich Adcock
Algemeen directeur
US$12.7m
Totale compensatie
| Percentage CEO-salaris | 6.54% |
| Dienstverband CEO | 5.8yrs |
| Eigendom CEO | 0.05% |
| Management gemiddelde ambtstermijn | 5.1yrs |
| Gemiddelde ambtstermijn bestuur | 5.8yrs |
Recente managementupdates
Recent updates
IBRX: FDA Review Timeline For Bladder Cancer Will Drive Future Upside
Analysts have reset their price target on ImmunityBio from $23 to $15. This reflects updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions.ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold
Summary ImmunityBio (IBRX) remains rated Hold as its $8bn+ valuation relies on future clinical and regulatory milestones, not current fundamentals. Anktiva's clinical data in NMIBC and NSCLC is encouraging, but competition is intense and label expansion is critical for long-term upside. Q1 2026 revenues reached $44.2m, but heavy operating losses and cash burn highlight the need for significant revenue ramp or new funding. Key risks include 'key man' dependence on Dr. Soon Shiong, lack of 2026 guidance, and the need for US approvals beyond NMIBC. Read the full article on Seeking Alpha
IBRX: Saudi Rollout And FDA Label Review Will Drive Future Upside
Analysts have raised their ImmunityBio price target from $11.00 to $12.00, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers of the revision. What’s in the News for ImmunityBio ImmunityBio shares recently reached a 3 month high, with investors focused on July catalysts including the commercial rollout of Anktiva in Saudi Arabia and upcoming updates on second quarter sales performance.
IBRX: Potential Index Inclusion Will Support Cancer Franchise Expansion
Analysts have lowered their ImmunityBio price target slightly from $13.50 to $13.00 as they refresh assumptions around discount rates, revenue growth, margins, and future P/E expectations. What’s in the News for ImmunityBio Retail traders are speculating that ImmunityBio stock could shift from the Russell 2000 to the Russell 1000 based on a cutoff around US$5.7b, with some traders expecting potential index fund buying and changes in volatility if inclusion occurs, according to recent Stocktwits sentiment data and after hours trading moves.Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results
Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power
Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking AlphaImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking AlphaAnalyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$992m |
| Mar 31 2026 | n/a | n/a | -US$855m |
| Dec 31 2025 | US$13m | US$832k | -US$351m |
| Sep 30 2025 | n/a | n/a | -US$349m |
| Jun 30 2025 | n/a | n/a | -US$367m |
| Mar 31 2025 | n/a | n/a | -US$409m |
| Dec 31 2024 | US$11m | US$802k | -US$414m |
| Sep 30 2024 | n/a | n/a | -US$588m |
| Jun 30 2024 | n/a | n/a | -US$598m |
| Mar 31 2024 | n/a | n/a | -US$601m |
| Dec 31 2023 | US$1m | US$796k | -US$583m |
| Sep 30 2023 | n/a | n/a | -US$458m |
| Jun 30 2023 | n/a | n/a | -US$473m |
| Mar 31 2023 | n/a | n/a | -US$430m |
| Dec 31 2022 | US$4m | US$791k | -US$417m |
| Sep 30 2022 | n/a | n/a | -US$400m |
| Jun 30 2022 | n/a | n/a | -US$376m |
| Mar 31 2022 | n/a | n/a | -US$370m |
| Dec 31 2021 | US$29m | US$765k | -US$347m |
| Sep 30 2021 | n/a | n/a | -US$323m |
| Jun 30 2021 | n/a | n/a | -US$301m |
| Mar 31 2021 | n/a | n/a | -US$264m |
| Dec 31 2020 | US$843k | US$141k | -US$222m |
Compensatie versus markt: De totale vergoeding ($USD 12.72M ) Rich } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.22M ).
Compensatie versus inkomsten: De vergoeding van Rich is gestegen terwijl het bedrijf verliesgevend is.
CEO
Rich Adcock (57 yo)
Mr. Richard Gerald Adcock, also known as Rich, has been the President of ImmunityBio, Inc. since March 05, 2021 and serves as its Director since March 29, 2021. He has been the Chief Executive Officer of I...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 11.8yrs | US$12.29m | 27.5% $ 2.3b | |
| President | 5.8yrs | US$12.72m | 0.053% $ 4.3m | |
| Chief Financial Officer | 7.1yrs | US$4.24m | 0.028% $ 2.3m | |
| Chief Accounting Officer | 4.8yrs | US$745.31k | 0.011% $ 895.4k | |
| Chief Corporate Affairs Officer & Director | 5.4yrs | geen gegevens | 0.26% $ 21.7m | |
| Chief Technology Officer | 3.6yrs | geen gegevens | geen gegevens | |
| Chief Communications Officer & Head of Patient Advocacy | 6.4yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Human Resources | 5.1yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer of Liquid Tumors & Cell Therapy | 1.5yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer | 6yrs | geen gegevens | geen gegevens | |
| Chief Science Officer of Cellular | no data | geen gegevens | geen gegevens | |
| Senior VP of Product Development & Cell Therapy Program | 2.6yrs | geen gegevens | geen gegevens |
Ervaren management: Het managementteam van IBRX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 11.8yrs | US$12.29m | 27.5% $ 2.3b | |
| President | 5.4yrs | US$12.72m | 0.053% $ 4.3m | |
| Chief Corporate Affairs Officer & Director | 19.6yrs | geen gegevens | 0.26% $ 21.7m | |
| Independent Director | 6yrs | US$477.28k | geen gegevens | |
| Independent Director | 5.5yrs | US$470.59k | 0.00075% $ 61.4k | |
| Independent Director | less than a year | US$302.74k | geen gegevens | |
| Independent Director | 11.1yrs | US$513.38k | 0.025% $ 2.1m | |
| Vice Chairman | no data | geen gegevens | geen gegevens | |
| Lead Independent Director | 7.2yrs | US$514.19k | 0.012% $ 969.2k | |
| Independent Director | 5.4yrs | US$489.19k | 0% $ 0 |
Ervaren bestuur: De raad van bestuur van IBRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/19 14:34 |
| Aandelenkoers aan het einde van de dag | 2026/08/18 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
ImmunityBio, Inc. wordt gevolgd door 7 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Suranjit Mukherjee | BTIG |
| Justin Zelin | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |